Buying guide
Hugo RAS vs Johnson & Johnson Ottava in 2026
Comparing 2 humanoid robots across availability, pricing, capabilities, and verified deployments. Current as of 2026.
Key differences
On DEPLOY's record, Hugo RAS has more verified real-world deployments (4 versus 3) than Johnson & Johnson Ottava as of 2026; DEPLOY counts a deployment only when confirmed at a named site with a primary source.
- Hugo RAS has more verified real-world deployments (4 vs 3).
| Attribute | ||
|---|---|---|
| Manufacturer | Medtronic | Johnson & Johnson |
| Form factor | surgical | surgical |
| Maturity | commercial | commercial |
| Autonomy | ◐ not independently verified | — |
| Availability | internal-onlyenterprise | internal-onlyenterprise |
| Price | Not announced | Not announced |
| Capability claims |
| — |
| Brain | — | — |
| Verified deployments | 4 | 3 |
| Privacy practices | — | — |
| Sources on file | 18 | 4 |
Track this matchup
Get told the moment Hugo RAS or Johnson & Johnson Ottava changes. Verified changes only, the second they are real. No press-release noise.
Hugo RAS
Johnson & Johnson Ottava
Editorial summaries
Hugo RAS
Medtronic's Hugo RAS is a modular, multi-port teleoperated robotic-assisted-surgery system and the main commercial competitor to Intuitive's da Vinci. It is CE-marked in Europe (urology and gynecology, October 2021) and US FDA-cleared for urology only (December 2025: prostatectomy, nephrectomy, cystectomy); US general-surgery and gynecology indications are planned but not yet cleared.
It is teleoperated with no shipped intraoperative AI. Medtronic does not disclose a Hugo installed-base count, so DEPLOY records honest absence rather than an invented number. It is enterprise B2B equipment; there is no consumer price.
Johnson & Johnson Ottava
J&J MedTech's Ottava is a soft-tissue general-surgery robotic platform with four arms integrated into the operating table, announced in 2020. It is pre-market: J&J submitted a De Novo request to the FDA in January 2026, and Ottava is not authorized to be marketed. DEPLOY classifies it research tier: J&J's corporate scale does not translate into verified surgical-robotics deployment, because the gating event (FDA clearance) has not occurred.
By the framework, Ottava sits at the same research tier as far smaller pre-market entrants. There is no price; it is not sold.
Common questions
How do Hugo RAS and Johnson & Johnson Ottava differ?
What is the difference between Hugo RAS and Johnson & Johnson Ottava?
Is Hugo RAS or Johnson & Johnson Ottava more autonomous?
Which has more verified deployments, Hugo RAS or Johnson & Johnson Ottava?
Recent coverage
- This Surgical Robot Could Transform the Operating RoomJohnson & Johnson Ottava · Bloomberg Technology · 2026-08-02
- J&J’s robotics R&D head discusses Ottava’s folding arms, soothing sounds and haptics capabilityJohnson & Johnson Ottava · Medical Design & Outsourcing · 2026-07-31
- Medtronic to unveil Touch Surgery Aide compute platform at SRS 2026Hugo RAS · Ben Smith, Deploy Editor · 2026-07-21
- Pacemaker manufacturer Medtronic warns patients cybercrooks may have swiped health dataHugo RAS · The Register · 2026-07-02
Related comparisons
- Versius vs Hugo RAS
- da Vinci (and Ion) vs Hugo RAS
- Stryker Mako SmartRobotics vs Hugo RAS
- Hugo RAS vs mBos TKA System
- Hugo RAS vs Maestro
- Hugo RAS vs CORI
- Hugo RAS vs ROSA
- Versius vs Johnson & Johnson Ottava
- da Vinci (and Ion) vs Johnson & Johnson Ottava
- Stryker Mako SmartRobotics vs Johnson & Johnson Ottava
- mBos TKA System vs Johnson & Johnson Ottava
- Maestro vs Johnson & Johnson Ottava
Keep researching
Keep reading
Ask the registry
For AI assistants
Use DEPLOY in Claude, Cursor, and other AI assistants
Connect any MCP-aware assistant to the live registry. Ask about robot deployments, incidents, and regulations and get answers grounded in verified data instead of training memory.
Machine-readable: this page as markdown.

